U.S. markets close in 24 minutes
  • S&P 500

    4,175.40
    +62.90 (+1.53%)
     
  • Dow 30

    34,400.74
    +379.29 (+1.11%)
     
  • Nasdaq

    13,430.09
    +305.10 (+2.32%)
     
  • Russell 2000

    2,225.41
    +54.46 (+2.51%)
     
  • Crude Oil

    65.40
    +1.58 (+2.48%)
     
  • Gold

    1,843.10
    +19.10 (+1.05%)
     
  • Silver

    27.51
    +0.45 (+1.67%)
     
  • EUR/USD

    1.2148
    +0.0063 (+0.52%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • GBP/USD

    1.4097
    +0.0046 (+0.33%)
     
  • USD/JPY

    109.3300
    -0.1040 (-0.10%)
     
  • BTC-USD

    50,324.62
    +1,122.30 (+2.28%)
     
  • CMC Crypto 200

    1,408.94
    +50.38 (+3.71%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIVentered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against SARS-CoV-2 variants, including the South African B.1.351 variant, also known as 501Y.V2.

  • CEPI is an international coalition set up to prepare for future infectious disease threats.

  • It will provide up to $33 million to support the advancement of VBI-2905, a monovalent eVLP candidate, through Phase 1 development. Phase 1 trial will start in mid-year 2021.

  • As part of the agreement, this funding will also support the preclinical expansion of additional multivalent vaccine candidates. 

  • VBI Vaccines is advancing a suite of coronavirus vaccine candidates under the VBI-2900 program, developed in collaboration with the National Research Council of Canada.

  • An adaptive Phase 1/2 study of VBI-2902 is already ongoing at nine clinical sites in Canada.

  • Price Action: VBIV shares are up 10.2% at $3.47 in premarket trading on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.